We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Affitech Signs Antibody Research and Licensing Agreement with Roche

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Affitech Signs Antibody Research and Licensing Agreement with Roche"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Affitech AS has announced that they have signed a research and licensing agreement with Roche to produce fully human monoclonal antibodies against an unnamed oncology target.

The agreement tasks Affitech with first using their proprietary phagemid library, high throughput screening technology and antibody engineering platforms to identify candidate antibodies which Roche would then utilize for further development and commercialization.

The financial terms of the collaboration include research fees, milestone payments and royalties on net sales upon commercialization of any product.

"These are exciting times for Affitech," commented Martin Welschof, Ph.D., Chief Executive Officer of Affitech. "We are delighted that Roche has chosen to partner with us based on our significant achievements to date in the human antibody field. Partnering is a key part of our twin-track strategy of generating revenue streams from collaborations parallel to developing our own therapeutic candidate pipeline.”

“This new agreement is the latest in a series of collaborations, also in oncology that we have made with some of the other global antibody companies including the US based Xoma and Peregrine Pharmaceuticals,” Welschof added.